

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

7,400

Open access books available

194,000

International authors and editors

210M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

14%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



# Ginger in the Prevention of Cardiovascular Diseases

*Begoña Cerdá, Javier Marhuenda, Raúl Arcusa, Débora Villaño, Purificación Ballester and Pilar Zafrilla*

## Abstract

Ginger, *Zingiber officinale*, is a member of the Zingiberaceae family, used in traditional medicine for treatment of a variety of conditions. Many pharmacological activities have been reported for this plant (anti-inflammatory, anti-tumorigenic, anti-apoptotic, anti-hyperglycemic, cancer-chemopreventive, and anti-lipidemic). Cardiovascular disease, which includes coronary artery disease, acute myocardial infarction, peripheral arterial disease, and stroke, is one of the leading causes of death worldwide. In recent years, several studies have described that ginger can control or improve some cardiovascular risk factors such as cholesterol levels, hypertension, or atherosclerosis. The aim of the present review is to summarize the effects of ginger bioactive compounds on cardiovascular diseases.

**Keywords:** cardiovascular disease, ginger, hypertension, obesity, gingerol, shogaol

## 1. Introduction

There is an urgent need to implement intervention measures and health policies to reduce mortality associated to cardiovascular disease (CVD), which will result in more adequate, healthy, and sustainable development per each country. CVD has caused 6.2 million deaths worldwide in people aged 30–70 years in 2019 [1].

Regarding cardiovascular health, there are certain modifiable risk factors that can be intervened upon to improve health. These factors include: hypertension, elevated fasting plasma glucose, elevated low-density lipoprotein (LDL) or cholesterol, and alterations in renal function. Environmental factors such as air and household pollution, smoking, low physical activity, and overweight and obesity are also included. In addition, in the case of women, the consumption of oral contraceptives and the presence of polycystic ovaries syndrome increase the risk of suffering CVD [2].

There are numerous studies linking diet and health, and this is most evident in the case of cardiovascular risk. Both dietary patterns, such as a diet rich in antioxidants, fiber (from vegetables, whole grains, fruits, nuts, pulses) fish, poor in processed foods (with high content in sugar or animal fats), together with the food intake containing specific bioactive substances or nutrients can modulate the risk factors [3, 4]. Therefore, changes in lifestyle and diet can prevent these diseases [5].

CVD is linked to the development of atherosclerosis and is directly related with an inflammatory response. This response is prompted by bad diet habits, sedentary lifestyle, obesity, and stress [6].

Herbal measurements are used to develop new drugs with higher potency and fewer adverse effects targeting the modulation of biological activities.

Ginger (*Zingiber officinale*) is among the medicinal plants with beneficial health effects that has been widely used in pharmaceutical products and food. Its crude extract is cardioprotective due to its antihypertensive, antiplatelet, and cardiotonic effects [7].

The term nutraceutical is used for any food or ingredient with a beneficial effect on health beyond the traditional nutritional effects; further, it has a positive impact on health, physical or cognitive state [8]. Numerous nutraceuticals are used for the prevention of CVDs, including ginger (see **Table 1**).

Apart from its cardioprotective effects, ginger has numerous properties such as antimicrobial, antioxidant, anti-inflammatory, anti-carcinogenic, and neurodegenerative diseases prevention. It prevents chemotherapy-induced emesis, nausea, and respiratory disorders [9, 10].

Ginger's flavor and aroma come from its volatile oils (~1–3% of the weight of fresh ginger) and nonvolatile pungent oleoresins. Further, the pharmacological properties are due to its oleoresin's composition, rich in zingerone (ZGR), gingerols (6/8/10-gingerols), and shogaols (6/8/10-shogaols and 6-hydroshogaol). The spiciness character of dried ginger rhizome comes from the gingerols, especially 6-gingerol. During drying, gingerols transform into ZGR, reducing pungency and providing a spicy-sweet aroma, and shogaols concentration increases [11].

Ginger inhibits lipid peroxidation through its antioxidant effect. 6-Gingerol increases Beclin1 expression to promote autophagy in human endothelial cells and inhibits *PI3K/AKT/mTOR* pathway signaling not affecting the cell cycle [12].

Ginger could prevent atherosclerosis, since consumption of a ginger extract has been observed to improve lipoprotein results in hamsters thanks to an increased activity of the liver enzyme CYP7A1 and decreased mRNA levels of intestinal cholesterol absorption proteins such as MTP, ACAT2, and NPC1L1 [13].

Nutraceuticals	Properties
PUFA n-3 (polyunsaturated fatty acid)	Arrhythmias, sudden death, hypertriglyceridemia, antiplatelet agents, anti-inflammatories
Q10 coenzyme	Antioxidant, antihypertensive
Vitamin D	Depression, atherosclerosis, valvular calcification
Resveratrol	Anti-inflammatories, antioxidant
Red yeast rice	Improves dyslipidemia
Phytosterols	Lowers cholesterol, LDL-C, antihypertensive
Flavonoids	Antiplatelet agents, anti-inflammatories antioxidant, antihypertensive
Dietary fiber	Dyslipidemia, metabolic syndrome decreases total cholesterol, LDL-C, triglycerides, blood glucose, and body weight
Ginger	Anti-inflammatories, antioxidant antiplatelet agent, antihypertensive
B complex	Reduces hyperhomocysteinemia

**Table 1.**  
*Nutraceuticals in the prevention of cardiovascular diseases [9].*

6-Gingerol regulates lipogenesis, fatty acid oxidation, mitochondrial dysfunction, and oxidative stress of aging rats. Several authors observed that 8-gingerol due to its antioxidant properties could inhibit melanogenesis in murine melanoma cells. In addition, it increases the activity of the antioxidant enzyme superoxide dismutase (SOD) and decreases the levels of malondialdehyde (MDA), a marker of lipid peroxidation, in a concentration-dependent manner [14, 15].

Inflammation associated with CVD induces an increase in proinflammatory cytokines such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-1 $\beta$  (IL-1 $\beta$ ), and interleukin-6 (IL-6). Several authors have observed that ginger significantly reduces TNF- $\alpha$  values, and 6-gingerol reduces the levels of inducible nitric oxide (NO) synthase enzyme and inflammatory factors [16].

Ginger can also be used in moderate obesity, a cardiovascular risk factor. Ginger increases lipolysis and thermogenesis and inhibits lipogenesis; therefore, it could be used to prevent obesity [17].

In summary, ginger consumption in the diet could improve cardiovascular health by lowering blood pressure, improving lipid profile, preventing obesity, improving glycemic control, and vascular health. The benefits of ginger on cardiovascular risk factors are mediated by transcription factors such as adenosine-monophosphate-activated protein kinase, peroxisome proliferator-activated receptors, peroxisome proliferator-activated protein kinase, and nuclear factor kappa B (NF- $\kappa$ B) [8, 18]. Having that in mind, the purpose of the present review chapter is to summarize the effects of bioactive compounds in ginger on CVD.

## 2. Cardiovascular risk factors

CVD is a group of disorders of the heart and blood vessels. It includes a large number of pathologies, among which it is worth highlighting: coronary heart disease, cerebrovascular diseases, peripheral arteriopathies, and rheumatic and congenital heart disease, among others. In most of them there is a common pathological process, atherosclerosis [19, 20]. This condition occurs when fat and cholesterol build up on the walls of blood vessels or in the arteries. This accumulation gives rise to atherosclerotic plaques. Over time, plaques can narrow blood vessels and cause problems throughout the body. If an artery becomes blocked, it can lead to a heart attack or stroke [21].

Cardiovascular risk factors are those that are associated with a greater probability of suffering from CVD. It is widely described that the most developed countries' lifestyles entail an increased risk of suffering from CVD. There are many studies that showed that a significant percentage of CVD and its mortality can be prevented by acting on cardiovascular risk factors [3].

Atherosclerosis is a multifactorial disease, in which several risk factors are involved [22]. The prevalence and potency of these risk factors vary. Cardiovascular risk factors improve CVD by reducing plaque formation.

Two types of risk factors can be differentiated: modifiable and non-modifiable. Pencina et al. established the importance of both and determined that the non-modifiable factors (sex, age, and race) account for between 63 and 80% of the risk factors, while the weight of the modifiable factors is much lower. But, control of modifiable risk factors leads to substantial reductions of cardiovascular events [23, 24].

## **2.1 Non-modifiable risk factors**

Non-modifiable risk factors are sex, age, race, and genotype. They are those that are not likely to be modified, therefore nothing can be done about them. It has been proven that cardiovascular risk is higher in men than in women, increases after 35 years, and Hispanics, Latinos, and Southeast Asians have a higher cardiovascular risk [24].

## **2.2 Modifiable risk factors**

Modifiable risk factors are hypertension; obesity and diabetes; dyslipidemias; chronic stress; diet; tobacco; and sedentary lifestyle [25]. They are those that are likely to be modified, where actions can be directed attempting to prevent and/or improve atherosclerosis and therefore CVD.

### *2.2.1 Hypertension*

Hypertension is the most important CVD risk factor. There is a direct relationship between increased blood pressure and the development of CVD. When properly treated, CVD mortality is reduced. Its pathophysiology is very complex and different mechanisms are involved, including the central nervous system, the immune system, and the neurohumoral system [26].

### *2.2.2 Obesity and diabetes*

The prevalence of obesity in the world is increasing in a very worrying way across all ages [27]. The relationship between obesity and CVD is clear. It has been shown how it contributes to atherosclerosis through different mechanisms. On the other hand, it must be taken into account that obesity is a risk factor for other comorbidities such as diabetes, sleep apnea, dyslipidemia, hypertension, and even cancer [28, 29].

### *2.2.3 Dyslipidemias*

Since lipids are involved in the formation of atherosclerotic plaque, especially LDL cholesterol and TG, increases of their plasmatic levels entail a risk of atherosclerosis and CVD. This is what happens in dyslipidemias. Reducing them is a fundamental therapeutic strategy to reduce CVD risk [30, 31].

### *2.2.4 Chronic stress*

It is one of the most important cardiovascular risk factors. Chronic stress is a situation maintained over time in which the body generates a nonspecific and systemic response as a result of exposure to negative external factors. The relationship between chronic stress and the risk of CVD has been widely demonstrated [32].

### *2.2.5 Diet*

It is clear that diet influences the maintenance of good cardiovascular health. And it is an essential tool to control other risk factors such as diabetes, obesity, dyslipidemia, and even hypertension. It has been proven that diets such as the Mediterranean



or DASH reduce cardiovascular risk. They are diets that improve markers of inflammation and oxidative stress and also contribute to improving the lipid and glycemic (improvement of insulin sensitivity) profiles, and endothelial function. In addition, they have proven antithrombotic properties. The consumption of fiber, omega-3 acids, vegetables and fruits, and whole grains seems to be decisive in reducing cardiovascular risk [33–36].

#### 2.2.6 Smoking

Tobacco continues to be one of the most important cardiovascular risk factors. Since its consumption increases the formation of atherosclerotic plaque, through an enhanced inflammation, endothelial dysfunction, arterial stiffness, and lipid profile [37]. In addition, its consumption increases the heart rate; myocardial contractility; thrombus formation by increased platelet activation and adhesion and procoagulant profile [38].


#### 2.2.7 Sedentary lifestyle

Regular and moderate physical activity, which modifies muscle tissue and adipose tissue, has been shown to have a positive impact on health. It reduces systemic inflammation and has an antiatherogenic effect. Therefore, lack of physical activity is a cardiovascular risk factor [39].

### 3. Bioactive compounds of ginger

Ginger, the rhizome of *Zingiber officinale* Roscoe that belongs to Zingiberaceae family, is commonly used as a spice or dietary supplement and has been widely used in traditional medicine throughout history [40]. Ginger has been identified as having a multitude of different bioactive compounds, including lipids, carbohydrates, terpenes, and phenolic compounds, and its pharmacological effects are largely due to phenolic compounds and terpenes [41, 42]. Ginger-derived terpenes ( $\alpha$ -zingiberene, camphene, ar-curcumene,  $\beta$ -phellandrene, E- $\alpha$  farnesene,  $\beta$ -bisabolene,  $\alpha$ -piene) [43] are known to have antioxidant, anti-inflammatory, antibacterial, antidiabetic, analgesic, gastroprotective, neuroprotective, and anti-carcinogenic properties [41]. Of the 400 types of compounds present in ginger, four phenolic compounds are mainly responsible for its pharmacological effects: gingerols, shogaols, paradols, and ZGR [44, 45]. There are also other types of compounds related to gingerol (8-gingerol, 10-gingerol, and 12-gingerol) and shogaol (1-dehydrogingerdione, 6-gingerdione, and 10-gingerdione) [42].

The main pungent and most abundant compound, 6-gingerol, which is present in fresh ginger, attenuates various chronic disorders. By dehydration and after long storage, this compound is converted into 6-shogaol, which is more stable and has greater pharmacological effects than its precursor 6-gingerol [46, 47]. 6-Shogaol is converted to 6-paradol by bacterial metabolism, and both possess similar anti-inflammatory and antioxidant properties [40, 47]. Antioxidant, antitumoral, antilipidemic, antibacterial, and anti-inflammatory actions are attributed to ZGR, and it is synthesized by reverse aldolization of gingerols when heating fresh ginger [47, 48]. **Figure 1** summarizes the metabolization pathways of 6-gingerol as a function of thermal processing.



**Figure 1.**  
*Properties and metabolism of gingerols.*

Zick et al. [49] observed that 6-shogaol and the 6-, 8-, and 10-gingerols have good bioavailability when consumed orally, being detected as sulfate and glucuronide conjugates. However, 6-gingerol has not been detected free in plasma after an oral dose of 2 g, despite it being the major compound in ginger extracts (2–64%) [50]. Pharmacokinetic studies showed that the half-life of the major compounds of ginger and its metabolites is approximately 1–3 hours. Based on bioavailability data, 6-, 8-, and 10-gingerol glucuronides and sulfates along with 6-shogaols could be good markers of ginger intake [50].

As for its therapeutic use, given its various anti-inflammatory, antimicrobial, anticancer, and antioxidant biological activities, ginger appears to be effective in the prevention and treatment of neurodegenerative, cardiovascular, obesity, diabetes mellitus, or respiratory disorders [45].

## 4. Effects of ginger in the prevention of cardiovascular disease

### 4.1 Antioxidant activity

Oxidative stress is increased under the condition in which there is a decrease in the body's antioxidant defenses; therefore, there is an imbalance between the production and elimination of reactive oxygen species (ROS). As a consequence of this imbalance, ROS accumulate, generating cellular damage in the different systems of the organism, since they produce lipid peroxidation [51, 52].

Ginger has great antioxidant activity; in fact, many of its therapeutic applications are due to this activity. That ginger has antioxidant activity is a fact that has been shown both in vitro and in vivo. Although studies on the effects to human are not as numerous, it is beginning to be verified that its intake is capable of increasing the concentration of antioxidant enzymes and decreasing oxidative stress markers in cancer patients [53]. Morvaridzadeh et al. carried out a systematic review and meta-analysis where they concluded that there is sufficient evidence to show that ginger intake

increases the levels of oxidative stress parameters [54]. There are many bioactive compounds in ginger that exhibit antioxidant activity, such as 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol. Of all of them, the one with the highest antioxidant activity in vitro is 6-gingerol, followed by 6-shogaol [55].

The mechanism involved in its antioxidant activity has to do both with preventing the appearance of free radicals [56] and with being able to eliminate them [57]. 6-Gingerol has been shown to be capable of inhibiting xanthine oxidase, an enzyme that catalyzes the oxidation of hypoxanthine to xanthine and of xanthine to uric acid in the last stage of purine metabolic degradation, with the production of reactive oxygen species [58]. In addition, it has been proven that this compound is capable of increasing superoxide dismutase and catalase activity, two antioxidant enzymes [53].

It has been seen how the antioxidant activity depends on the time of harvest of ginger, if it is early, the antioxidant activity is higher, decreasing if the harvest is done later [59].

## 4.2 Anti-inflammatory activity

Another of the great biological activities attributed to ginger is its anti-inflammatory activity. Inflammation is one of the body's first responses to a risk situation [60]. When that inflammation is maintained over time, is then problematic. Today it is known that there are many diseases in which inflammation plays a determining role, in fact it is being studied how low-grade systemic inflammation is related to the development of different pathologies (autoimmune diseases, metabolic diseases, CVDs, cancer) [61, 62]. In chronic or low-grade inflammation, different proinflammatory factors are released, such as cytokines and prostaglandins [61].

Many researchers have shown that ginger reduces different proinflammatory markers such as: NF- $\kappa$ B, signal transducer activators of transcription (STAT), proteins of the Nod-like receptor family (NLRP), receptors toll-like (TLR), mitogen-activated protein kinase (MAPK), and mTOR (mTOR) pathways, in addition to inhibiting several proinflammatory cytokines [19, 58].

In the systematic review and meta-analysis carried out by Jalali et al, it is shown how ginger is capable of significantly reducing the levels of different proinflammatory parameters such as IL-6, TAC, CRP, TNF- $\alpha$ , MDA, and the serum prostaglandin E2 (PGE2) [63]. Song et al. have examined how ginger extract is capable of reducing proinflammatory markers produced by *Helicobacter pylori*. The expressions of interleukin (IL)-8, TNF- $\alpha$ , IL-6, inducible NOS (iNOS), and IFN- $\gamma$  were reduced [64].

The most active compounds from the anti-inflammatory point of view of ginger are 6-shogaol, 6-gingerol, and 6-dehydroshogaol [45, 65, 66]. It has been described how 6-shogaol has an anti-inflammatory effect because it inhibits the production of PGE2 and proinflammatory cytokines (IL-1 $\beta$  and TNF- $\alpha$ ) and decreases the expression of cyclooxygenase-2 (COX-2), p38 mitogen-activated protein kinase (MAPK), and nuclear NF- $\kappa$ B [45]. In other studies, 6-shogaol has been shown to inhibit LPS-induced iNOS and COX-2 expression in macrophages [67]. Furthermore, studies showed that 6-shogaol could protect against lipopolysaccharide (LPS)-induced toxicity in murine astrocytes [68].

## 4.3 Antiobesity activity

Worldwide, obesity has become the main pandemic of the twenty-first century [69, 70], as the rates of this pathology have increased considerably during the last



decades [71, 72]. According to the World Health Organization (WHO), obesity is characterized by an excessive accumulation of fatty tissue in the body, causing harmful effects on health [73]. Concerning problems associated with obesity are mainly its deleterious effect on other non-detectable diseases: CVDs, hypertension, nonalcoholic fatty liver disease, various types of cancer, and hyperlipidemia [74, 75]. In addition, it should be noted that patients with obesity show worse prognosis against COVID-19 infection and higher mortality rates [76, 77]. Additionally, it induces low-grade inflammation, oxidative stress, and contributes in the etiology of type 2 diabetes mellitus [78]. In recent years, natural compounds have aroused great interest in the prevention/treatment of obesity, and several studies have shown that ginger seems to be effective for this pathology [45].

It seems that gingerenone-A has a more potent inhibitory effect on adipogenesis and lipid accumulation than gingerols and 6-shogaol in 3T3-L1 preadipocyte cells, while it appears to activate the adenine monophosphate (AMP)-activated protein kinase (AMPK) pathway modulating fatty acid metabolism, thus attenuating obesity [79]. For its part, the daily dose of 2 g of ginger powder in obese women resulted in a decrease in body mass index (BMI) [80]. Daily dose of ginger powder also appears to increase fat oxidation in humans [81]. Several studies have shown that ginger can reduce body weight by increasing thermogenesis through catecholamines as well as lipolysis of white adipose tissue [78]. Therefore, it seems evident that both ginger and certain bioactive components are effective against obesity by enhancing lipolysis and inhibiting adipogenesis.

#### **4.4 Antidiabetic activity**

Diabetes is a serious metabolic disorder characterized by an abnormal increase in blood glucose. For this reason, several research studies have considered evaluating the possible effect of ginger and its main bioactive components in the reduction of blood glucose [82].

It has been shown that the administration of 6-gingerol stimulates the activity of glycogen synthase 1 and at the same time favors the translocation of the glucose transporter type 4 (GLUT-4) to the cell membrane, favoring insulin to allow glucose entry in skeletal muscles and subsequent storage as glycogen [83]. Ginger consumption seems to reduce our values of glycosylated hemoglobin (HbA1c), fasting plasma glucose, insulin, total cholesterol, and triglycerides in patients with type 2 diabetes mellitus [84].

#### **4.5 Effect of ginger on lipid profile**

The greatest cause of atherosclerosis is characterized by altered blood lipid values and consequently CVD. In addition, the factors previously mentioned, such as overweight/obesity and high blood glucose values, are factors that will have a greater effect on this pathology.

Impaired blood lipid values are the major cause of CVD. In a recent systematic review and meta-analysis of clinical trials in 2018, it was concluded that ginger has a favorable effect in reducing triglycerides and LDL cholesterol, without significant reductions in total cholesterol. However, doses lower than 2 g/day of dairy ginger powder seem to be more effective in lowering both triglycerides and total cholesterol [83]. Since it is a safe and inexpensive supplement, it could be used to improve the lipid profile of subjects and thus prevent CVD.

Clinical studies have been conducted to evaluate the effect of ginger supplementation on the lipid profile of different populations. Doses of up to 1.8 g/day have been shown to significantly reduce triglyceride, total and LDL cholesterol levels compared with placebo in obese patients treated with metformin (**Table 2**) [85].

Significant lowering effect of ginger compared with placebo has also been observed in [86, 87]. However, other studies failed to observe a positive effect, and ginger supplementation exerted no effect on blood lipid profiles and body composition [88] and no significant differences in cholesterol lipoproteins profile between ginger and placebo [89]. In some cases, the results are inconsistent, with significant differences in some markers as LDL/HDL ratio after ginger intake and no changes on mean levels of total cholesterol or triglycerides [90], or reductions in levels of serum triglycerides and LDL with no effects on total cholesterol or high-density lipoprotein (HDL) [91].

Levels of apolipoprotein B and apolipoprotein B/apolipoprotein A-I ratio reduced and apolipoprotein A1 increased after ginger supplementation (2 g/day) for 12 weeks [92]. The overexpression of ApoA1 could explain the increases observed in HDL levels in some trials.

Population	Intervention	Outcomes	Ref.
Obese Egyptian patients with new-onset T2DM ( <i>n</i> = 80) 30–60 years	600 mg 3 times/day 8 weeks	↓ BMI, ↓ TC, ↓ LDL-C, ↓ TG ↑ HDL-C ginger vs. placebo	[86]
Hyperlipidemic non diabetic patients ( <i>n</i> = 45 ginger, 40 placebo)	3 g/day 45 days	↓ TC, ↓ TG ginger vs. placebo	[87]
Obese men ( <i>n</i> = 32) 18–30 years	1 g/day 10 weeks with/out resistance training	n.s. TC, TG, LDL-C, HDL-C ginger vs. placebo ↓ TC, ↓ fat mass training groups	[88]
Obese women with breast cancer ( <i>n</i> = 40)	3 g/day, 6 weeks, with/out exercise training	↓ LDL, ↓ TC, ↓ TG, ↑ HDL ginger + exercise	[89]
T2DM patients ( <i>n</i> = 64) 38–65 years	2 g/day 8 weeks	↓ LDL, ↓ TG	[90]
T2DM patients ( <i>n</i> = 63) 20–60 years	1.6 g/day 12 weeks	↓ TC, ↓ TG	[85]
Obese women ( <i>n</i> = 80) 18–45 years	2 g/day 12 weeks vs. placebo	↓ TG ginger vs. placebo Both groups: ↓ TC, ↓ TG, ↓ LDL/HDL ratio, ↓ TC/HDL ratio, ↑ HDL	[91]
T2DM ( <i>n</i> = 50) 20–60 years	2 g/day 12 weeks	↓ ApoB, ↓ ApoB/Apo A1 ratio, ↑ Apo A1	[92]
T2DM ( <i>n</i> = 88)	3 g/day 8 weeks	↓ TC	[93]
Hyperlipidemic patients ( <i>n</i> = 100), 35–60 years	3 g/day 30 days	↓ TC	[94]
T2DM ( <i>n</i> = 50)	2 g/day 10 weeks	↓ LDL/HDL ratio ginger vs. placebo	[83]
Menopausal women ( <i>n</i> = 160) 50–60 years	1 g/day 16 weeks vs. 900 mg/day garlic with/out aerobic exercise	No effects in ginger groups ↓ TC, ↓ LDL with garlic	[95]

**Table 2.**  
*Summary of the effect of ginger supplementation on the lipid profile in different clinical trials and populations.*

Discrepancies in the results could be due to the different characteristics of the populations studied, stage of the disease, pharmacological treatments, format of ginger administered.

Meta-analysis studies have concluded that ginger significantly increases HDL levels and reduces plasma levels of triglycerides and total cholesterol, with different extent depending on the clinical condition (hyperlipidemia and T2DM) [93, 94]. The analysis conducted by Pourmasoumi et al. [83] revealed a better effect of total cholesterol and triglycerides with doses < 2 g/day and a maximum of 50 days of supplementation.

Among the different mechanisms of action attributed to ginger components is the inhibition of intestinal lipase enzymes, thus avoiding fat hydrolysis and absorption and the increase in plasma levels of triglycerides. In case of cholesterol, its decrease in plasma concentrations has been related to an inhibition in cellular cholesterol synthesis and an increase of hepatic enzyme activity of cholesterol 7  $\alpha$ -hydroxylase CYP7A1a, implicated in the conversion of cholesterol into bile acids for its clearance by fecal excretion [95]. Ginger is implicated in the inhibition of expression of adipogenesis and lipogenesis genes as PPAR  $\gamma$  and carbohydrate-responsive element-binding protein (ChREBP) gene expression in the liver [66]. ChREBP reduced expression further decreases the expression of glucogenic and lipogenic enzymes (as fatty acid synthase, stearyl-CoA-desaturase-1, acetyl-CoA carboxylase 1, among others [95].

#### 4.6 Effect of ginger on blood pressure

It is well known that healthy diet and lifestyle can control blood pressure and endothelial dysfunction. Inflammation associated with cardiovascular events contributes to hypertension by affecting the renin-angiotensin system [96]. Elevated blood pressure (BP) has also been known to be a strong risk factor cardiovascular [97].

The compounds in ginger responsible for its antihypertensive effect are 6-shogaol and 9-gingerol. These compounds reduce cholesterol and LDL levels, inhibit atheroma plaque formation, and increase vessel elasticity. They also reduce the release of inflammatory mediators responsible for endothelial dysfunction by decreasing intercellular adhesion molecule 1 (ICAM-1) levels [98]. Several authors [99] show the antihypertensive effect of ginger in volunteers with mean  $\leq 50$  years, with ginger doses  $\geq 3$  g/day, and during an intervention period  $\leq 8$  weeks. This effect could be due to its antioxidant activity.

A systematic review with 345 participants from six clinical trials showed that ginger consumption has favorable effects on blood pressure. These authors observed that increasing ginger intake decreased the probability of ischemic heart disease and hypertension [100]. This result coincides with that observed in a clinical trial with 4628 participants in which the efficacy of ginger in coronary heart disease and as an antihypertensive was observed [101].

#### 4.7 Antiplatelet aggregation activity of ginger

Platelet aggregation and activation play an important role in developing thrombosis and atherosclerosis. Numerous nutrients and bioactive compounds have a potential role in platelet function and may decrease cardiovascular risk. These include berries, caffeine, chocolate, garlic, ginger, the omega-3 polyunsaturated fatty acids (PUFA), onion, and tomato [102].

ZGR is a compound (phenolic alkanose) found in *Zingiber officinale*. It exhibits anti-apoptotic, anti-inflammatory, and protective properties against cardiovascular

events such as myocardial infarction. Several authors have observed its anticoagulant and antithrombotic properties. This compound inhibits platelet aggregation induced by adenosine diphosphate (ADP), and U46619 (not thrombin), Tx2 inhibitor, inhibits the catalytic activity of factor Xa (FXa) toward its substrate S-2222 in a non-competitive inhibition model, reduces P-selectin and PAC-1 expressions in platelets, and reduces activated partial thromboplastin time [103].

Several authors [104] observed that consumption of a 10 g dose of powdered ginger after 4 hours significantly reduced ADP- and adrenaline-induced platelet aggregation. McEwen analyzed the *in vitro* antiplatelet activity of ginger and showed that gingerol, its analogues (1 and 5), paradol and shogaol, exhibited antiplatelet activity with IC<sub>50</sub> values between 5 and 7  $\mu$ M [18]. To be noted, aspirin inhibitory effect shows IC<sub>50</sub> values of  $20 \pm 11 \mu$ M, and paradol shows IC<sub>50</sub> values of  $4 \pm 1 \mu$ M.

Ginger has a vascular protective effect mediated by different mechanisms such as reduction of inflammation and oxidative stress, increase of nitric oxide synthesis, which is a potent vasodilator, the promotion of autophagy, and inhibition of vascular smooth muscle cell [105].

Comparing different ginger compounds, several investigators have shown that 6-gingerol and 6-shogaol showed the most potent bioactivity against cholesterol (Chol), arachidonic acid (AA), thrombin, and PAF-induced platelet aggregation [106]. The 6-paradol, 10-dehydrogingerol, 10-gingerol showed the most significant inhibition of AA-induced aggregation [107].

Nurtjahja-Tjendraputra et al. observed that 8-paradol is the most effective anticoagulant, being a COX-1 inhibitor [108].

Thomson et al. fed rats with ginger aqueous extract and observed a decrease in triglyceride, thromboxane-B2 cholesterol and PGE2 levels, and in adenosine deaminase (ADA) activity of plaques, together with an increase in adenosine levels. In this way, it favors vasodilatation, reducing the complications of hypertension and preventing from unnecessary platelet aggregation [108].

## 5. Conclusions

Ginger contains diverse bioactive compounds and demonstrates multiple bioactive properties. It is a potent antioxidant, anti-inflammatory, regulator of lipid profile, inhibitor of VSMC proliferation, blocker of voltage-dependent Ca<sup>2+</sup> channels, inhibitor of platelet aggregation, regulator of endothelial dysfunction and NO synthesis, enhancer of cholesterol efflux from macrophages, inhibitor of angiogenesis, and promoter of autophagy.

The biological activities, health benefits, and cardioprotective properties of ginger/ginger constituents along with related mechanisms of action gave new insights to show new avenues in the treatment of CVDs.

It is valuable to explore new anti-platelet aggregation drugs based on the skeleton of [n]-paradol or other principles reported from the *Zingiber* series.

## Acronyms and abbreviations

ACAT2	acetyl-CoA acetyltransferase 2
ADA	adenosine deaminase
ADP	adenosine diphosphate



AMP	adenine monophosphate
AMPK	activated protein kinase
BMI	body mass index
ChREBP	carbohydrate-responsive element-binding protein
GLUT-4	glucose transporter type 4
COX-1	cyclooxygenase-1
COX-2	cyclooxygenase-2
CVD	cardiovascular diseases
DASH	dietary approaches to stop hypertension
FXa	coagulation factor Xa
Ginger	<i>Zingiber officinale</i>
HbA1c	glycosylated hemoglobin
HDL	high-density lipoprotein
HUVECs	human umbilical endothelial cells
ICAM-1	intercellular adhesion molecule 1
IL	interleukin
iNOS	inducible NOS
LDL	low-density lipoprotein
LPS	lipopolysaccharide
MAPK	mitogen-activated protein kinase
mRNA	messenger ribonucleic acid
mTOR	mammalian target of rapamycin
MTP	microsomal triglyceride transfer protein
NF-κB	factor kappa B
NLRP	nod-like receptor
NO	oxide nitric
NOS	oxide nitric synthase
NPCA1L1	Niemann-Pick disease, type C1, gene-like 1
PAC-1	is a mouse monoclonal antibody
PGE2	prostaglandin E2
PUFA	polyunsaturated fatty acids
ROS	reactive oxidative species
S-2222	substrate S-2222 in a non-competitive inhibition model
SOD	superoxide dismutase
STAT	signal transducer activators of transcription
TLR	receptors toll-like
TNF-α	tumor necrosis tumoral alpha
U46619	a stable thromboxane receptor (TP receptor) agonist
VSMC	vascular smooth muscle cell
WHO	World Health Organization
ZGR	zingerone

## Conflict of interest

The authors declare no conflict of interest.




IntechOpen

### Author details

Begoña Cerdá, Javier Marhuenda, Raúl Arcusa\*, Débora Villaño,  
Purificación Ballester and Pilar Zafrilla  
Faculty of Health Sciences, Pharmacy Department, Universidad Católica de San  
Antonio, Murcia, Spain

\*Address all correspondence to: [rarcusa@ucam.edu](mailto:rarcusa@ucam.edu)

### IntechOpen

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

## References

- [1] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators\*. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* (London, England). 2018;**392**:1789-1858
- [2] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet* (London, England). 2020;**396**:1223-1249
- [3] Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet*. 2004;**364**:937-952
- [4] Marhuenda J, Villaño D, Cerdá B, et al. Cardiovascular disease and nutrition. In: Mózsik G, Figler M, editors. *Nutrition in Health and Disease*. Rijeka: IntechOpen; 2019. DOI: 10.5772/intechopen.84370
- [5] Rosengren A, Smyth A, Rangarajan S, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: The Prospective Urban Rural Epidemiologic (PURE) study. *The Lancet Global Health*. 2019;**7**:e748-e760
- [6] Arcusa R, Carrillo JÁ, Xandri-Martínez R, et al. Effects of a fruit and vegetable-based nutraceutical on biomarkers of inflammation and oxidative status in the plasma of a healthy population: A placebo-controlled, double-blind, and randomized clinical trial. *Molecules*. 2021;**26**. DOI: 10.3390/molecules26123604
- [7] Fakhri S, Patra JK, Das SK, et al. Ginger and heart health: From mechanisms to therapeutics. *Current Molecular Pharmacology*. 2021;**14**:943-959
- [8] Ma R-H, Ni Z-J, Zhu Y-Y, et al. A recent update on the multifaceted health benefits associated with ginger and its bioactive components. *Food & Function*. 2021;**12**:519-542
- [9] Wei C-K, Tsai Y-H, Korinek M, et al. 6-Paradol and 6-shogaol, the pungent compounds of ginger, promote glucose utilization in adipocytes and myotubes, and 6-paradol reduces blood glucose in high-fat diet-fed mice. *International Journal of Molecular Sciences*. 2017;**18**:168
- [10] Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. *Biomaterials*. 2016;**101**:321-340
- [11] Guarneri M, Mercado N, Suhar C. Integrative approaches for cardiovascular disease. *Nutrition in Clinical Practice*. 2009;**24**:701-708
- [12] Wang S, Sun X, Jiang L, et al. 6-Gingerol induces autophagy to protect HUVECs survival from apoptosis. *Chemico-Biological Interactions*. 2016;**256**:249-256
- [13] Lei L, Liu Y, Wang X, et al. Plasma cholesterol-lowering activity of gingerol- and shogaol-enriched extract is mediated by increasing sterol excretion. *Journal of Agricultural and Food Chemistry*. 2014;**62**:10515-10521
- [14] Kiptiyah K, Widodo W, Ciptadi G, et al. 10-Gingerol as an inducer of apoptosis through HTR1A in cumulus

cells: In-vitro and in-silico studies. Journal of Taibah University Medical Sciences. 2017;**12**:397-406

[15] Li J, Wang S, Yao L, et al. 6-Gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. Toxicology and Applied Pharmacology. 2019;**362**:125-135

[16] Morvaridzadeh M, Fazelian S, Agah S, et al. Effect of ginger (*Zingiber officinale*) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. Cytokine. 2020;**135**:155224

[17] Ebrahimzadeh Attari V, Malek Mahdavi A, Javadivala Z, et al. A systematic review of the anti-obesity and weight lowering effect of ginger (*Zingiber officinale* Roscoe) and its mechanisms of action. Phytotherapy Research. 2018;**32**:577-585

[18] McEwen BJ. The influence of herbal medicine on platelet function and coagulation: A narrative review. Seminars in Thrombosis and Hemostasis. 2015;**41**:300-314

[19] Steven S, Frenis K, Oelze M, et al. Vascular inflammation and oxidative stress: Major triggers for cardiovascular disease. Oxidative Medicine and Cellular Longevity. 2019;**2019**:7092151. DOI: 10.1155/2019/7092151

[20] Arnett DK et al. Writing committee members circulation. Circulation. 2019;**140**:596-646

[21] Zhu Y, Xian X, Wang Z, et al. biomolecules Research Progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018;**23**:80. DOI: 10.3390/biom8030080

[22] Schloss MJ, Swirski FK, Nahrendorf M. Modifiable cardiovascular risk, hematopoiesis, and innate immunity. Circulation Research. 2020;**126**:1242-1259. DOI: 10.1161/CIRCRESAHA.120.315936

[23] Pencina MJ, Navar AM, Wojdyla D, et al. Quantifying importance of major risk factors for coronary heart disease. Circulation. 2019;**139**:1603-1611

[24] Ghoshhajra BB, Hedgire SS, Kowek LMH, et al. ACR appropriateness Criteria® asymptomatic patient at risk for coronary artery disease: 2021 update. Journal of the American College of Radiology. 2021;**18**:S2-S12

[25] Atar D, Jukema JW, Molemans B, et al. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021;**319**:51-61

[26] Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease and mortality in 155,722 individuals from 21 high-, middle-, and low-income countries HHS Public Access. Lancet. 2020;**395**:795-808

[27] Boccellino M, D'Angelo S. Anti-obesity effects of polyphenol intake: Current status and future possibilities. International Journal of Molecular Sciences. 2020;**21**:5642

[28] Csige I, Ujvárosy D, Szabó Z, et al. The impact of obesity on the cardiovascular system. Journal of Diabetes Research. 2018;**2018**:3407306. DOI: 10.1155/2018/3407306

[29] Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable

long-term weight management. Journal of the American Association of Nurse Practitioners. 2017;**29**:S3-S14. DOI: 10.1002/2327-6924.12510

[30] Trautwein EA, McKay S. The role of specific components of a plant-based diet in management of dyslipidemia and the impact on cardiovascular risk. Nutrients 2020;**12**: 2671. DOI: 10.3390/nu12092671

[31] CPG ESCC for PG. 2019. ESC/ EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;**290**:140-205

[32] Yao B-C, Meng L-B, Hao M-L, et al. Chronic stress: A critical risk factor for atherosclerosis. The Journal of International Medical Research. 2019;**47**:1429-1440

[33] Ditano-Vázquez P, Torres-Peña JD, Galeano-Valle F, et al. The fluid aspect of the Mediterranean diet in the prevention and management of cardiovascular disease and diabetes: The role of polyphenol content in moderate consumption of wine and olive oil. Nutrients. 2019;**11**:2833. DOI: 10.3390/nu11112833

[34] Dobrosielski DA, Papandreou C, Patil SP, et al. Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk. The European Respiratory Review. 2017;**26**:160110. DOI: 10.1183/16000617.0110-2016

[35] Lechner K, Von Schacky C, McKenzie AL, et al. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. European Journal of Preventive Cardiology. 2020;**27**:394-406

[36] Dekker Nitert M, Groen B, Li H, et al. Interactions between therapeutics for metabolic disease, cardiovascular risk

factors, and gut microbiota. Frontiers in Cellular and Infection Microbiology. 2020;**10**:530160

[37] Kondo T, Nakano Y, Adachi S, et al. Effects of tobacco smoking on cardiovascular disease. Circulation Journal. 2019;**83**:1980-1985

[38] Digiacomo SI, Jazayeri M-A, Barua RS, et al. Environmental tobacco smoke and cardiovascular disease. International Journal of Environmental Research and Public Health. 2018;**16**:96. DOI: 10.3390/ijerph16010096

[39] Patterson R, Mcnamara E, Tainio M, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: A systematic review and dose response meta-analysis. European Journal of Epidemiology. 2018;**33**:811-829. DOI: 10.1007/s10654-018-0380-1

[40] Mohd Yusof YA. Gingerol and its role in chronic diseases. Advances in Experimental Medicine and Biology. 2016;**929**:177-207

[41] Kiyama R. Nutritional implications of ginger: Chemistry, biological activities and signaling pathways. The Journal of Nutritional Biochemistry. 2020;**86**:108486

[42] Jafarzadeh A, Jafarzadeh S, Nemati M. Therapeutic potential of ginger against COVID-19: Is there enough evidence? Journal of Traditional Chinese Medical Sciences. 2021;**8**:267-279

[43] An K, Zhao D, Wang Z, et al. Comparison of different drying methods on Chinese ginger (*Zingiber officinale* Roscoe): Changes in volatiles, chemical profile, antioxidant properties, and microstructure. Food Chemistry. 2016;**197**:1292-1300



- [44] Prasad S, Tyagi AK. Ginger and its constituents: Role in prevention and treatment of gastrointestinal cancer. *Gastroenterology Research and Practice*. 2015;2015:142979
- [45] Mao Q-Q, Xu X-Y, Cao S-Y, et al. Bioactive compounds and bioactivities of ginger (*Zingiber officinale* Roscoe). *Foods* (Basel, Switzerland). 2019;8:185. DOI: 10.3390/foods8060185
- [46] Kou X, Wang X, Ji R, et al. Occurrence, biological activity and metabolism of 6-shogaol. *Food & Function*. 2018;9:1310-1327
- [47] Choi JG, Kim SY, Jeong M, et al. Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders. *Pharmacology & Therapeutics*. 2018;182:56-69
- [48] Jafarzadeh A, Nemati M. Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties. *Journal of Neuroimmunology*. 2018;324:54-75
- [49] Zick SM, Djuric Z, Ruffin MT, et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. *Cancer Epidemiology Biomarkers Prevention*. 2008;17:1930-1936
- [50] Yu Y, Zick S, Li X, et al. Examination of the pharmacokinetics of active ingredients of ginger in humans. *The AAPS Journal*. 2011;13:417-426
- [51] Alsahli MA, Almatroodi SA, Almatroudi A, et al. 6-Gingerol, a major ingredient of ginger attenuates diethylnitrosamine-induced liver injury in rats through the modulation of oxidative stress and anti-inflammatory activity. *Mediators Inflamm*; 2021. DOI: 10.1155/2021/6661937
- [52] Jelic MD, Mandic AD, Maricic SM, et al. Oxidative stress and its role in cancer. *Journal of Cancer Research and Therapeutics*. 2021;17:22
- [53] Danwilai K, Konmun J, Sripanidkulchai B-O, et al. Cancer Management and Research Dovepress Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: A pilot study. *Cancer Management and Research*. 2017:9-11
- [54] Morvaridzadeh M, Sadeghi E, Agah S, et al. Effect of ginger (*Zingiber officinale*) supplementation on oxidative stress parameters: A systematic review and meta-analysis. *Journal of Food Biochemistry*. 2021;45:e13612
- [55] Mohammed A, Ali A, Elamin M, et al. Total phenolic and flavonoid contents and antioxidant activity of ginger (*Zingiber officinale* Rosc.) rhizome, callus and callus treated with some elicitors. *Journal, Genetic Engineering & Biotechnology*. 2018;16:677-682
- [56] Ali A, Gilani AH. Medicinal value of ginger with focus on its use in nausea and vomiting of pregnancy. *International Journal of Food Properties*. 2007;10:269-278
- [57] Sueishi Y, Masamoto H, Kotake Y. Heat treatments of ginger root modify but not diminish its antioxidant activity as measured with multiple free radical scavenging (MULTIS) method. *Journal of Clinical Biochemistry and Nutrition*. 2019;64:143-147
- [58] Rondanelli M, Fossari F, Vecchio V, et al. Clinical trials on pain lowering effect of ginger: A narrative review. *Physiological Research*. 2020;34:2843-2856. DOI: 10.1002/ptr.6730
- [59] Li H, Rafie R, Xu Z, et al. Phytochemical profile and anti-oxidation



activity changes during ginger (*Zingiber officinale*) harvest: Baby ginger attenuates lipid accumulation and ameliorates glucose uptake in HepG2 cells. *International Journal of Food Sciences and Nutrition*. 2021;**10**:133-144. DOI: 10.1002/fsn3.2654

[60] León-Pedroza JI, González-Tapia LA, del Olmo-Gil E, et al. Low-grade systemic inflammation and the development of metabolic diseases: From the molecular evidence to the clinical practice. *Cirugía y Cir (English Ed)*. 2015;**83**:543-551

[61] Duraisamy K, Janigro D, Riquelme MA, et al. The importance and control of low-grade inflammation due to damage of cellular barrier systems that may lead to systemic inflammation. *Frontiers in Neurology*. 2019;**1**:533

[62] Rea IM, Gibson DS, McGilligan V, et al. Age and age-related diseases: Role of inflammation triggers and cytokines. *Front Immunol*. 2018;**9**:586

[63] Jalali M, Mahmoodi M, Moosavian SP, et al. The effects of ginger supplementation on markers of inflammatory and oxidative stress: A systematic review and meta-analysis of clinical trials. *Phyther Research*. 2020;**34**:1723-1733

[64] Song M-Y, Lee D-Y, Park S-Y, et al. Steamed ginger extract exerts anti-inflammatory effects in helicobacter pylori-infected gastric epithelial cells through inhibition of NF- $\kappa$ B. *Journal of Cancer Prevention*. 2021;**26**:289

[65] Zadorozhna M, Mangieri D. Molecular sciences mechanisms of chemopreventive and therapeutic proprieties of ginger extracts in cancer. Epub ahead of print 2021. DOI: 10.3390/ijms22126599

[66] Unuofin JO, Masuku NP, Paimo OK, et al. Ginger from Farmyard to Town:

Nutritional and pharmacological applications. *Frontiers in Pharmacology*. 2021;**12**:779352. DOI: 10.3389/fphar.2021.779352

[67] Chen C-Y, Kao C-L, Liu C-M. The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway. *International Journal of Molecular Sciences*. 2018;**19**:2729 DOI: 10.3390/ijms19092729

[68] Han Q, Yuan Q, Meng X, et al. 6-Shogaol attenuates LPS-induced inflammation in BV2 microglia cells by activating PPAR- $\gamma$ . *Oncotarget*. 2017;**8**:42001-42006

[69] Meldrum DR, Morris MA, Gambone JC. Obesity pandemic: Causes, consequences, and solutions-but do we have the will? *Fertility and Sterility*. 2017;**107**:833-839

[70] Huang H, Yan Z, Chen Y, et al. A social contagious model of the obesity epidemic. *Scientific Reports*. 2016;**6**:37961

[71] Williams EP, Mesidor M, Winters K, et al. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. *Current Obesity Reports*. 2015;**4**:363-370

[72] Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014;**384**:766-781

[73] Serna A, Marhuenda J, Arcusa R, et al. Effectiveness of a polyphenolic extract (*Lippia citriodora* and *Hibiscus sabdariffa*) on appetite regulation in overweight and obese grade I population: An 8-week randomized, double-blind,

cross-over, placebo-controlled trial. European Journal of Nutrition. 2021;1-17

[74] Savino P. Obesidad y enfermedades no transmisibles relacionadas con la nutrición. Rev Colomb Cir. 2011;26:180-195

[75] Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:1-20

[76] Zhou Y, Chi J, Lv W, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes/Metabolism Research and Reviews. 2021;37:e3377

[77] Yu W, Rohli KE, Yang S, et al. Impact of obesity on COVID-19 patients. Journal of Diabetes and its Complications. 2021;35:107817

[78] Tramontin NDS, Luciano TF, de Marques O, et al. Ginger and avocado as nutraceuticals for obesity and its comorbidities. Phytotherapy Research. 2020;34:1282-1290

[79] Suk S, Kwon GT, Lee E, et al. Gingerenone A, a polyphenol present in ginger, suppresses obesity and adipose tissue inflammation in high-fat diet-fed mice. Molecular Nutrition & Food Research. 2017;61:1700139

[80] Attari VE, Ostadrahimi A, Jafarabadi MA, et al. Changes of serum adipocytokines and body weight following *Zingiber officinale* supplementation in obese women: A RCT. European Journal of Nutrition. 2016;55:2129-2136

[81] Miyamoto M, Matsuzaki K, Katakura M, et al. Oral intake of encapsulated dried ginger root powder hardly affects human thermoregulatory function, but appears to facilitate fat

utilization. International Journal of Biometeorology. 2015;59:1461-1474

[82] Bin SM, Mohsin M, Bin NA, et al. [6]-Gingerol, from *Zingiber officinale*, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic  $\beta$ -cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia. BMC Complementary and Alternative Medicine. 2017;17:1-13

[83] Pourmasoumi M, Hadi A, Rafie N, et al. The effect of ginger supplementation on lipid profile: A systematic review and meta-analysis of clinical trials. Phytomedicine. 2018;43:28-36

[84] Arablou T, Aryaeian N, Valizadeh M, et al. The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. International Journal of Food Sciences and Nutrition. 2014;65:515-520

[85] El Gayar MH, Aboromia MMM, Ibrahim NA, et al. Effects of ginger powder supplementation on glycemic status and lipid profile in newly diagnosed obese patients with type 2 diabetes mellitus. Obesity Medicine; 14. Epub ahead of print June 2019. DOI: 10.1016/j.obmed.2019.100094

[86] Alizadeh-Navaei R, Roozbeh F, Saravi M, et al. Investigation of the effect of ginger on the lipid levels: A double blind controlled clinical trial. Saudi Medical Journal. 2008;29:1280-1284

[87] Arablou T, Aryaeian N. The effect of ginger (*Zingiber officinale*) as an ancient medicinal plant on improving blood lipids. Journal of Herbal Medicine. 2018;12:11-15

- [88] Atashak S, Peeri M, Jafari A, et al. Effects of ginger supplementation and resistance training on lipid profiles and body composition in obese men. *Journal of Medical Plants Research*. 2011;5:3827-3832
- [89] Attari VE, Mahluji S, Jafarabadi MA, et al. Effects of supplementation with ginger (*Zingiber officinale* Roscoe) on Serum glucose, lipid profile and oxidative stress in obese women: A randomized, placebo-controlled clinical trial. *Pharmaceutical Science*. 2015;21:184-191
- [90] Makhdoomi Arzati M, Mohammadzadeh Honarvar N, Saedisomeolia A, et al. The effects of ginger on fasting blood sugar, hemoglobin A1c, and lipid profiles in patients with type 2 diabetes. *International Journal of Endocrinology and Metabolism*. 2017;15:e57927. DOI: 10.5812/ijem.57927
- [91] Mahluji S, Attari VE, Mobasser M, et al. Effects of ginger (*Zingiber officinale*) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients. *International Journal of Food Sciences and Nutrition*. 2013;64:682-686
- [92] Khandouzi N, Shidfar F, Rajab A, et al. The effects of ginger on fasting blood sugar, hemoglobin A1c, apolipoprotein B, apolipoprotein A-I and malondialdehyde in type 2 diabetic patients. *Iranian Journal of Pharmaceutical Research (IJPR)*. 2015;14:131-140
- [93] Jafarnejad S, Keshavarz SA, Mahbubi S, et al. Effect of ginger (*Zingiber officinale*) on blood glucose and lipid concentrations in diabetic and hyperlipidemic subjects: A meta-analysis of randomized controlled trials. *Journal of Functional Foods*. 2017;29:127-134
- [94] Mazidi M, Gao HK, Rezaie P, et al. The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: A systematic review and meta-analysis. *Food and Nutrition Research*; 2016;60: 2613. DOI: 10.3402/fnr.v60.32613
- [95] Gao H, Guan T, Li C, et al. Treatment with ginger ameliorates fructose-induced fatty liver and hypertriglyceridemia in rats: Modulation of the hepatic carbohydrate response element-binding protein-mediated pathway. *Evidence-Based Complementary and Alternative Medicine*. 2012;2012:570948. DOI: 10.1155/2012/570948
- [96] Mahn K, Borrás C, Knock GA, et al. Dietary soy isoflavone-induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. *The FASEB Journal*. 2005;19:1755-1757
- [97] Kafeshani M, Entezari MH, Karimian J, et al. A comparative study of the effect of green tea and sour tea on blood pressure and lipid profile in healthy adult men. *ARYA Atherosclerosis*. 2017;13:109
- [98] Azimi P, Ghiasvand R, Feizi A, et al. Effect of cinnamon, cardamom, saffron and ginger consumption on blood pressure and a marker of endothelial function in patients with type 2 diabetes mellitus: A randomized controlled clinical trial. *Blood Pressure*. 2016;25:133-140
- [99] Hasani H, Arab A, Hadi A, et al. Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials. *Phytherapy Research*. 2019;33:1639-1647
- [100] Wang Y, Yu H, Zhang X, et al. Evaluation of daily ginger consumption for the prevention of chronic diseases in

adults: A cross-sectional study. *Nutrition*. 2017;**36**:79-84

[101] McEwen BJ. The influence of diet and nutrients on platelet function. *Seminars in Thrombosis and Hemostasis*. 2014;**40**:214-226

[102] Lee W, Ku S-K, Kim M-A, et al. Anti-factor Xa activities of zingerone with anti-platelet aggregation activity. *Food and Chemical Toxicology*. 2017;**105**:186-193

[103] Bordia A, Verma SK, Srivastava KC. Effect of ginger (*Zingiber officinale* Rosc.) and fenugreek (*Trigonella foenumgraecum* L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*. 1997;**56**:379-384

[104] Vázquez-Fresno R, Rosana ARR, Sajed T, et al. Herbs and spices—Biomarkers of intake based on human intervention studies: A systematic review. *Genes & Nutrition*. 2019;**14**:18

[105] Liao Y-R, Leu Y-L, Chan Y-Y, et al. Anti-platelet aggregation and vasorelaxing effects of the constituents of the rhizomes of *Zingiber officinale*. *Molecules*. 2012;**17**:8928-8937

[106] Akinyemi AJ, Thomé GR, Morsch VM, et al. Dietary supplementation of ginger and turmeric rhizomes modulates platelets ectonucleotidase and adenosine deaminase activities in normotensive and hypertensive rats. *Phytotherapy Research*. 2016;**30**:1156-1163

[107] Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, et al. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. *Thrombosis Research*. 2003;**111**:259-265

[108] Thomson M, Al-Qattan KK, Al-Sawan SM, et al. The use of ginger (*Zingiber officinale* Rosc.) as a potential anti-inflammatory and antithrombotic agent. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*. 2002;**67**:475-478